Skip to content

Mineralys Therapeutics, Inc.

MLYS

CIK 0001933414

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$161.76M
+13.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.44
+37.4% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$116.89M
Q1 Apr 2026
Cash
$112.78M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
82.5M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings